425 related articles for article (PubMed ID: 24590685)
21. Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone.
Kastritis E; Roussou M; Gavriatopoulou M; Kanellias N; Migkou M; Eleutherakis-Papaiakovou E; Ziogas DC; Fotiou D; Ntanasis-Stathopoulos I; Dialoupi I; Giannouli S; Tsirigotis P; Delimpasi S; Mparmparousi D; Spyropoulou-Vlachou M; Xirokosta A; Terpos E; Dimopoulos MA
Blood Adv; 2019 Dec; 3(23):4095-4103. PubMed ID: 31821457
[TBL] [Abstract][Full Text] [Related]
22. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG
Leuk Res; 2021 May; 104():106576. PubMed ID: 33839618
[TBL] [Abstract][Full Text] [Related]
23. A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial.
Hou J; Du X; Jin J; Cai Z; Chen F; Zhou DB; Yu L; Ke X; Li X; Wu D; Meng F; Ai H; Zhang J; Wortman-Vayn H; Chen N; Mei J; Wang J
J Hematol Oncol; 2013 Jun; 6():41. PubMed ID: 23782711
[TBL] [Abstract][Full Text] [Related]
24. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
Weisel KC; Dimopoulos MA; Moreau P; Lacy MQ; Song KW; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Knop S; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel J
Haematologica; 2016 Jul; 101(7):872-8. PubMed ID: 27081177
[TBL] [Abstract][Full Text] [Related]
25. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Mark TM; Forsberg PA; Rossi AC; Pearse RN; Pekle KA; Perry A; Boyer A; Tegnestam L; Jayabalan D; Coleman M; Niesvizky R
Blood Adv; 2019 Feb; 3(4):603-611. PubMed ID: 30792190
[TBL] [Abstract][Full Text] [Related]
26. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
Mark TM; Coleman M; Niesvizky R
Leuk Res; 2014 May; 38(5):517-24. PubMed ID: 24690110
[TBL] [Abstract][Full Text] [Related]
27. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
Lacy MQ; Allred JB; Gertz MA; Hayman SR; Short KD; Buadi F; Dispenzieri A; Kumar S; Greipp PR; Lust JA; Russell SJ; Dingli D; Zeldenrust S; Fonseca R; Bergsagel PL; Roy V; Stewart AK; Laumann K; Mandrekar SJ; Reeder C; Rajkumar SV; Mikhael JR
Blood; 2011 Sep; 118(11):2970-5. PubMed ID: 21690557
[TBL] [Abstract][Full Text] [Related]
28. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Schjesvold FH; Dimopoulos MA; Delimpasi S; Robak P; Coriu D; Legiec W; Pour L; Špička I; Masszi T; Doronin V; Minarik J; Salogub G; Alekseeva Y; Lazzaro A; Maisnar V; Mikala G; Rosiñol L; Liberati AM; Symeonidis A; Moody V; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Hájek R; Mateos MV; Richardson PG; Sonneveld P;
Lancet Haematol; 2022 Feb; 9(2):e98-e110. PubMed ID: 35032434
[TBL] [Abstract][Full Text] [Related]
29. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
Leleu X; Attal M; Arnulf B; Moreau P; Traulle C; Marit G; Mathiot C; Petillon MO; Macro M; Roussel M; Pegourie B; Kolb B; Stoppa AM; Hennache B; Bréchignac S; Meuleman N; Thielemans B; Garderet L; Royer B; Hulin C; Benboubker L; Decaux O; Escoffre-Barbe M; Michallet M; Caillot D; Fermand JP; Avet-Loiseau H; Facon T;
Blood; 2013 Mar; 121(11):1968-75. PubMed ID: 23319574
[TBL] [Abstract][Full Text] [Related]
30. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Richardson PG; Siegel D; Baz R; Kelley SL; Munshi NC; Laubach J; Sullivan D; Alsina M; Schlossman R; Ghobrial IM; Doss D; Loughney N; McBride L; Bilotti E; Anand P; Nardelli L; Wear S; Larkins G; Chen M; Zaki MH; Jacques C; Anderson KC
Blood; 2013 Mar; 121(11):1961-7. PubMed ID: 23243282
[TBL] [Abstract][Full Text] [Related]
31. Pomalidomide for patients with multiple myeloma.
Gras J
Drugs Today (Barc); 2013 Sep; 49(9):555-62. PubMed ID: 24086951
[TBL] [Abstract][Full Text] [Related]
32. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Dimopoulos MA; Dytfeld D; Grosicki S; Moreau P; Takezako N; Hori M; Leleu X; LeBlanc R; Suzuki K; Raab MS; Richardson PG; Popa McKiver M; Jou YM; Shelat SG; Robbins M; Rafferty B; San-Miguel J
N Engl J Med; 2018 Nov; 379(19):1811-1822. PubMed ID: 30403938
[TBL] [Abstract][Full Text] [Related]
33. Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series.
Richter J; Biran N; Duma N; Vesole DH; Siegel D
Hematol Oncol; 2017 Jun; 35(2):246-251. PubMed ID: 27018162
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
35. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
Richardson PG; Mark TM; Lacy MQ
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S36-44. PubMed ID: 23786844
[TBL] [Abstract][Full Text] [Related]
36. Pomalidomide.
Engelhardt M; Ajayi S; Reinhardt H; Müller SJ; Dold SM; Wäsch R
Recent Results Cancer Res; 2018; 212():169-185. PubMed ID: 30069630
[TBL] [Abstract][Full Text] [Related]
37. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
Richardson PG; Hofmeister CC; Raje NS; Siegel DS; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J; Doss D; Zaki MH; Bensmaine A; Herring J; Li Y; Watkins L; Chen MS; Anderson KC
Leukemia; 2017 Dec; 31(12):2695-2701. PubMed ID: 28642620
[TBL] [Abstract][Full Text] [Related]
38. Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.
Van Sanden S; Ito T; Diels J; Vogel M; Belch A; Oriol A
Oncologist; 2018 Mar; 23(3):279-287. PubMed ID: 29192016
[TBL] [Abstract][Full Text] [Related]
39. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
Raab MS; Engelhardt M; Blank A; Goldschmidt H; Agis H; Blau IW; Einsele H; Ferstl B; Schub N; Röllig C; Weisel K; Winderlich M; Griese J; Härtle S; Weirather J; Jarutat T; Peschel C; Chatterjee M
Lancet Haematol; 2020 May; 7(5):e381-e394. PubMed ID: 32171061
[TBL] [Abstract][Full Text] [Related]
40. Pomalidomide. A last-line treatment option for multiple myeloma.
Prescrire Int; 2014 Nov; 23(154):257-9. PubMed ID: 25954788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
